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Pre-PCI Post-PCI P Value
Proximal Average
luminal diameter(ALD)
2.45  0.65 2.55  0.59 <0.05
Reference diameter 1.88  0.38 1.99  0.27 <0.05
Minimal lumen
diameter (MLD)
0.42  0.35 1.66  0.28 <0.0001
%Diameter
stenosis(DS)
77.0  19.1 16.5  11.1 <0.0001
Distal ALD 1.35  0.49 1.56  0.31 <0.0001
Total stented length 39.2  19.4
Acute gain 1.90  0.49
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: Strut tissue coverage was classiﬁed according to published criteria (O-
SES vs. ZES, meanSD): Apposed uncovered struts, three-months: 6.14.4%
vs. 17.118.7% (n¼8 vs. n¼31, p¼0.631), six-months: 4.65.9% vs.
10.312.0% (n¼21 vs. n¼7, p¼0.068), nine-months: 1.51.8% vs. 6.58.9%
(n¼5 vs. n¼8, p¼0.190). Malapposed uncovered struts three-months: 6.212.8%
vs. 5.07.5% (p¼0.982), six-months: 4.35.6% vs. 3.34.5% (p¼ 0.629), nine-
months: 1.32.1% vs. 1.11.2% (p¼0.748). The intra-group analysis found no
statistical differences between the observed time-points. Neointimal thickness
was: three-months: 94.833.5 vs. 96.335.7 (p¼0.760), six-months: 102.929.0
vs. 92.234.6mm (p¼0.264), nine-months: 98.634.8 vs. 161.382.0mm
(p¼0.070). To discriminate mature and immature tissue coverage OCT based
grey scale signal intensity (GSI) analysis was assessed. We found no statistical
differences either for intra-group and the inter-group comparison. Concerning 12-
months follow-up patients no statistical differences were found for clinical
follow-up.
Conclusions: No statistical differences between O-SES and ZES concerning stent
struts coverage as well as GSI based quality assessments were found. The data show
generally comparable healing characteristics and neointimal formation of the O-SES
and ZES.
TCT-602
Clinical And Angiographic Results In Patients With Very Small Coronary Vessel
After BiolimusA9–eluting Stents Implantation
Soichiro Enomoto1, Takenori Domei2, Toru Mazaki3, Shoichi Kuramitsu4,
Makoto Hyodo5, Shinichi Shirai6, kenji Ando7
1Tenri hospital, Nara, Japan, 2Kokura Memorial Hospital, Kitakyushu, Fukuoka,
3Kokura Memorial Hospital, Fukuoka, Japan, 4Kokura Memorial Hospital,
Kitakyushu, Japan, 5Kokura Memorial Hospital, kitakyusyu, Fukuoka, 6Kokura
Memorial Hospiral, Kitakyushu, Fukuoka, 7kokura memorial hospital, kitakyusyu,
Fukuoka
Background: Percutaneous coronary interventions (PCI) to small-diameter vessels
remain an important challenge because of increased complications.
Methods: Between May 2011 and January 2012, 83 patients with very small
coronary vessels (reference vessel diameter < 2.25 mm) were submitted to PCI.
Biolimus-eluting stent (BES) was deployed at a low pressure with long inﬂation
time.
Results: Two cases of distal edge dissection were observed and one of them
needed additional stent implantation. There was no major adverse cardiac event
(MACE), including cardiac death, myocardial infarction (MI) and target lesion
revascularization (TLR) during the initial hospitalization. The angiographic data
is shown in table. Average luminal diameters(ALD) in distal segments mark-
edly increased from baseline to post procedure (1.350.49 mm vs. 1.560.31,
p< 0.0001). At 12-months follow-up, the rate of MACE and TLR was 11.1%
and 8.1%, respectively. Distal ALD in patients without TLR signiﬁcantly
increased from post procedure to follow-up (1.540.30 mm vs. 1.680.32 mm,
p< 0.01).Conclusions: BES implantation to very small coronary vessels achieved a high
clinical success. Vessel diameter distal to stent markedly increased immediately after
initial PCI and became larger at 1-year follow-up in case without TLR.B176 JACC Vol 64/11/Suppl B j September 13TCT-603
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Background: Fatigue fracture of coronary stents is a recurring problem that may lead
to an array of complications. It is important, both for stent design and selection, to
better understand this phenomenon. In this study, the fatigue resistance of three
coronary stent designs was qualitatively compared through means of ﬁnite element
analysis in a patient-speciﬁc setting.
Methods: Finite element computer simulations were used to virtually deploy and
realistically deform three stent designs within a human coronary artery. The three stent
models (Element, Boston Scientiﬁc; Multi-Link 8, Abbott Vascular; Biomatrix Flex,
Biosensors) were generated based on micro-computed tomography scans of device
samples. The vessel geometry and deformation was modeled based on biplane ﬂuo-
roscopy images of a human right coronary artery at diastole and systole. After device
deployment and recoil the fatigue safety of the stents was evaluated by imposing a
cyclic deformation to the vessel model. The risk of fatigue fracture of different stents
or fracture locations within a speciﬁc stent is assessed based on these computer
simulations, and relative comparisons between stents can be made. Predicted fracture
locations and relative fatigue resistances are put into perspective of fatigue fracture
data reported in literature.
Results: For the investigated patient, the Element was the stent with the highest
relative fatigue safety. Relative to the Element stent, the fatigue safety of the Multi-
Link 8 and Biomatrix Flex stent was 95% and 91%, respectively. Unlike the Element,
both the Multi-Link 8 and Biomatrix Flex showed regions of low fatigue safety in the
connectors between rings. These results are in close agreement with fatigue fracture
data reported in literature.
Conclusions: The proposed method for comparing the relative fatigue resistance of
coronary devices in a patient-speciﬁc setting can be used to optimize device design
and selection.
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Background: Early reports revealed that a novel abluminal groove-ﬁlled biode-
gradable polymer sirolimus-eluting stent (named target eluting technology) FIRE-
HAWK (MicroPort Medical, Shanghai, China) was safe and effective in 1-year
follow-up in a large cohort of patients from the TARGET clinical program. We aimed
to investigate the long-term clinical outcomes of this novel stent.
Methods: An objective performance criterion (OPC) study was required by the
China Food and Drug Administration for new drug-eluting stent. The primary
endpoint, target lesion failure (TLF), was deﬁned as the composite of cardiac
death, target vessel myocardial infarction (TV-MI), or ischemia-driven target lesion
revascularization (iTLR) at 12 months. A patient-level pooled data derived from–17, 2014 j TCT Abstracts/Stents - Drug-eluting: Novel Metallic DES
